FDA grants orphan drug designation to potential treatment of STXBP1 developmental and epileptic encephalopathy
Research that was carried out by Baylor College of Medicine and Texas Children's Hospital doctors has led to the U.S. Food ...
FierceBiotech26d
Lykos accepts FDA’s view that reviving rejected MDMA therapy’s fortunes requires fresh phase 3 trial
Interim CEO Michael Mullette and chief medical officer David Hough ... have had a “productive meeting” with the FDA, the company said in a brief statement on Oct. 18.